(redirected from Urokinase-Type Plasminogen Activator)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to Urokinase-Type Plasminogen Activator: Plasminogen activator inhibitor


tr.v. ac·ti·vat·ed, ac·ti·vat·ing, ac·ti·vates
1. To set in motion; make active or more active.
2. To organize or create (a military unit, for example): activate the National Guard.
3. To treat (sewage) with aeration and bacteria to aid decomposition.
4. Chemistry To accelerate a reaction in, as by heat.
5. Physics To make (a substance) radioactive.
6. Biology To convert (a molecule or cell) into a form that carries out a specific action: activate an enzyme; activate B cells.

ac′ti·va′tion n.
ac′ti·va′tor n.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


(ˈæk təˌveɪ tər)

1. a person or thing that activates.
2. Chem., Biochem. a catalyst.
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.activator - (biology) any agency bringing about activationactivator - (biology) any agency bringing about activation; a molecule that increases the activity of an enzyme or a protein that increases the production of a gene product in DNA transcription
substance - the real physical matter of which a person or thing consists; "DNA is the substance of our genes"
biological science, biology - the science that studies living organisms
activating agent - (mineral extraction) a surface-active chemical used in flotation process to increase the attraction to a specific mineral
catalyst, accelerator - (chemistry) a substance that initiates or accelerates a chemical reaction without itself being affected
sensitiser, sensitizer - (chemistry) a substance other than a catalyst that facilitates the start of a catalytic reaction
inhibitor - a substance that retards or stops an activity
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.


[ˈæktɪˌveɪtəʳ] Nactivador m
Collins Spanish Dictionary - Complete and Unabridged 8th Edition 2005 © William Collins Sons & Co. Ltd. 1971, 1988 © HarperCollins Publishers 1992, 1993, 1996, 1997, 2000, 2003, 2005


n activador m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Serum soluble urokinase-type plasminogen activator receptor levels in male patients with acute exacerbation of schizophrenia.
Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.
Bhattachar for their insightful comment [1] on our article suggesting a role of low-grade cellular-based inflammation as indicated by elevated soluble urokinase-type plasminogen activator receptor (suPAR) plasma concentrationon in the pathogenesis of high altitude pulmonary edema (HAPE) [2].
Taccone et al., "Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients," Journal of Critical Care, vol.
Endothelial cells produce, storage, and release tissue-type plasminogen activator and urokinase-type plasminogen activator, which are fibrinolytic activators.
Urokinase-type plasminogen activator activity was analyzed using a chromogenic assay as described previously [17].
uPA binds tightly ([K.sub.D] < 1nm) [76] to cell-surface receptor urokinase-type plasminogen activator receptor (uPAR) through its GFD [77, 78], although it also binds and activates plasminogen on platelets, which do not express uPAR [79].
Zlobec, "Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer," Human Pathology, vol.
Schmitt, "Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination," Journal of Clinical Oncology, vol.
Soluble urokinase-type plasminogen activator receptor (suPAR) has recently been suggested as a potential circulating factor in FSGS [9-13].
Elevated plasma soluble urokinase-type plasminogen activator receptor (suPAR) levels are associated with declines in estimated glomerular filtration rate and may predict progression to clinical chronic kidney disease, new research suggests.